Is there a common denominator for drug companies who are required to submit additional information during the approval process?
Editor's note · Context
Moran questions if smaller companies face more scrutiny in drug approval.
Share
More from Jerry Moran
I thank the gentleman from Virginia. Mr. President, with your permission, I would like to yield to my colleague from Kansas, Senator Marshall. The PRESIDING OFFICER. The Senator from Kansas.
today, I want to recognize National Donate Life Month. Throughout the month of April, our Nation observes National Donate Life Month to highlight the lifesaving impact organ donations continue to have in Kansas and around the world. Each…
we are in the process of reaching a conclusion in debating at least the first step--maybe now the second step--of reconciliation. It is an opportunity for us to make the Tax Code more permanent, an opportunity for us to reduce spending and…
I intend to ask for a unanimous consent agreement in regard to this issue of our care and the well-being of our veterans. I would indicate that, to my knowledge, the Department of Veterans Affairs has 1,500 fewer employees today than it…





